CareDx, Inc
CDNA
Hisse Senetlerindeki Sıralama
#4637
CareDx, Inc. is a global innovator specializing in the discovery, development,... CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Hisse Fiyatı
$63.44
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$3.28B
Değişim (1 gün)
-4.85%
Değişim (1 yıl)
340.25%
Ülke
US
Ticaret CareDx, Inc (CDNA)
Kategori
Healthcare
CareDx, Inc (CDNA) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -0.92%
CareDx, Inc şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -0.92%'dir. 2023 yılı sonunda şirketin faaliyet marjı -72.55% idi.
CareDx, Inc için 2012 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -0.92% | -107.53% |
| 2024 | 12.21% | -116.83% |
| 2023 | -72.55% | 202.29% |
| 2022 | -24.00% | 139.28% |
| 2021 | -10.03% | 8.79% |
| 2020 | -9.22% | -52.25% |
| 2019 | -19.31% | -5.11% |
| 2018 | -20.35% | -51.55% |
| 2017 | -42.00% | -54.29% |
| 2016 | -91.88% | 116.70% |
| 2015 | -42.40% | -1,025.76% |
| 2014 | 4.58% | -218.04% |
| 2013 | -3.88% | -66.11% |
| 2012 | -11.45% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 17.97% | -119.53% |
US
|
|
| 20.42% | -122.20% |
US
|
|
| -10.70% | -88.37% |
US
|
|
| 0.00% | - |
CN
|
|
| 22.23% | -124.16% |
US
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.